Artera, a company specializing in AI-driven patient communication, has partnered with Atlantic Health to deploy AI agents aimed at improving patient outreach for colonoscopy procedures. The initiative focuses on automating pre-procedure engagement to enhance preparation and support preventive care efforts.
Atlantic Health, a not-for-profit health system operating across New Jersey, Pennsylvania, and the New York metropolitan area, is using Artera’s AI agents to conduct outbound calls to patients approximately one week prior to scheduled colonoscopies. These agents are designed to encourage patients to review preparation materials while also addressing a wide range of clinical and operational inquiries.
The AI system is capable of answering more than 80 pre-approved questions and supports multilingual communication, enabling broader accessibility across diverse patient populations. This marks Atlantic Health’s first deployment of AI agents specifically for outbound patient communication, representing a shift toward integrating automation into preventive care workflows.
By embedding AI into patient engagement processes, the health system aims to reduce administrative burden while improving adherence to pre-procedure instructions, a key factor in the effectiveness of colonoscopy screenings.
Guillaume de Zwirek, CEO and cofounder of Artera, commented on the collaboration, stating, “It’s great to see a team like Atlantic Health show what’s possible when you stop talking about AI and start using it. They’ve moved quickly to put AI where it actually matters for patients. We love partnering with teams to think big, move fast and scale impact.”
The deployment aligns with broader developments within Artera, including continued investment in its AI capabilities and leadership expansion. In December, the company raised $65 million in growth funding, following earlier capital raises of $20 million in 2024 and $90 million at launch. Artera has also strengthened its executive team with the appointment of Damon Lanphear, formerly of Amazon Web Services and Amazon Devices, as chief technology officer.
Additionally, the company has achieved regulatory milestones, including FDA de novo authorization and Breakthrough Device Designation for its ArteraAI Prostate tool, which supports clinical decision-making in prostate cancer care.
The partnership reflects increasing adoption of AI-driven communication tools to support patient engagement and streamline preventive healthcare delivery.
Click here for the original news story.
